The stock of Iterum Therapeutics Plc (ITRM) has seen a -2.48% decrease in the past week, with a 0.85% gain in the past month, and a -21.33% decrease in the past quarter. The volatility ratio for the week is 7.54%, and the volatility levels for the past 30 days are at 8.76% for ITRM. The simple moving average for the past 20 days is -0.69% for ITRM’s stock, with a -21.38% simple moving average for the past 200 days.
Is It Worth Investing in Iterum Therapeutics Plc (NASDAQ: ITRM) Right Now?
The 36-month beta value for ITRM is also noteworthy at 2.26. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ITRM is 21.67M, and at present, short sellers hold a 2.05% of that float. The average trading volume of ITRM on September 02, 2024 was 246.43K shares.
ITRM) stock’s latest price update
The stock price of Iterum Therapeutics Plc (NASDAQ: ITRM) has jumped by 4.42 compared to previous close of 1.13. Despite this, the company has seen a fall of -2.48% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-16 that Iterum Therapeutics plc (NASDAQ:ITRM ) Q2 2024 Results Conference Call August 14, 2024 8:30 AM ET Company Participants Louise Barrett – Senior Vice President of Legal Affairs & Secretary Corey Fishman – President, CEO & Director Judith Matthews – Chief Financial Officer Conference Call Participants Jason McCarthy – Maxim Group Operator Good morning, everyone. Welcome to Iterum Therapeutics Second Quarter 2024 Financial Results and Business Update.
Analysts’ Opinion of ITRM
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ITRM reach a price target of $2.50. The rating they have provided for ITRM stocks is “Buy” according to the report published on March 15th, 2021.
RBC Capital Mkts gave a rating of “Sector Perform” to ITRM, setting the target price at $2 in the report published on June 02nd of the previous year.
ITRM Trading at -4.28% from the 50-Day Moving Average
After a stumble in the market that brought ITRM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.80% of loss for the given period.
Volatility was left at 8.76%, however, over the last 30 days, the volatility rate increased by 7.54%, as shares sank -1.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.61% upper at present.
During the last 5 trading sessions, ITRM fell by -2.48%, which changed the moving average for the period of 200-days by +53.27% in comparison to the 20-day moving average, which settled at $1.1873. In addition, Iterum Therapeutics Plc saw -40.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITRM starting from Dunne Michael W., who purchase 25,000 shares at the price of $1.40 back on Dec 22 ’23. After this action, Dunne Michael W. now owns 113,754 shares of Iterum Therapeutics Plc, valued at $35,000 using the latest closing price.
Dunne Michael W., the Director of Iterum Therapeutics Plc, purchase 10,000 shares at $1.84 during a trade that took place back on Dec 18 ’23, which means that Dunne Michael W. is holding 88,754 shares at $18,442 based on the most recent closing price.
Stock Fundamentals for ITRM
Current profitability levels for the company are sitting at:
- -14.6 for the present operating margin
- 0.66 for the gross margin
The net margin for Iterum Therapeutics Plc stands at -10.82. The total capital return value is set at 14.71. Equity return is now at value -555.68, with -86.93 for asset returns.
Based on Iterum Therapeutics Plc (ITRM), the company’s capital structure generated 2.02 points at debt to capital in total, while cash flow to debt ratio is standing at -1.92. The debt to equity ratio resting at -1.98. The interest coverage ratio of the stock is -21.7.
Currently, EBITDA for the company is -45.72 million with net debt to EBITDA at -0.45. When we switch over and look at the enterprise to sales, we see a ratio of 16.58. The receivables turnover for the company is 13.44for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.77.
Conclusion
In summary, Iterum Therapeutics Plc (ITRM) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
